The Use of Collagenase in the Treatment of Peyronie’s Disease

Gelbard, Martin K.; Lindner, Arie; Kaufman, Joseph J.

doi:10.1016/s0022-5347(17)47123-0

Cited by 111 publications

(63 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 y later, Gelbard et al 26 published data on the use of a single intralesional collagenase injection in 31 patients. The results of this study were encouraging, with objective improvement in 20 patients within 4 weeks.…”

Section: Intralesional Therapymentioning

confidence: 99%

Review of current nonsurgical management of Peyronie's disease

Levine

2003

Int J Impot Res

View full text Add to dashboard Cite

The current nonsurgical treatment options for men with Peyronie's disease is reviewed. The treatments currently employed and published in the English literature are discussed. A wide variety of nonsurgical treatment options are available to the practicing physician, including oral and topical medications, intralesional injection therapy, as well as employing external energy sources to drive medicine into the tunica albuginea by iontophoresis or direct stimulation of plaque change by shock wave therapy. Nonsurgical treatment of Peyronie's disease clearly has a place in the armamentarium of the practicing urologist. Oral therapy appears to have little therapeutic benefit. Injection and topical approaches deserve further attention. Yet, no single treatment stands out as the most effective remedy for all men with Peyronie's disease. Further controlled, large-scale studies are necessary to establish the benefits of these nonsurgical approaches. In the meantime, combination therapy appears to make sense in the nonsurgical treatment of men with Peyronie's disease.

show abstract

Section: Intralesional Therapymentioning

confidence: 99%

Review of current nonsurgical management of Peyronie's disease

Levine

2003

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…[2] Direct injectable forms of CCh are marketed under Xiaflex, and Xiapex (Auxilium Pharmaceuticals in the USA and by Sobi in Europe, respectively) as a novel local therapy for PD. The impact of collagenase as a potential intralesional agent for PD treatment was first examined by Gelbard et al [34] in the 1980s. Intralesional injection of CCh in 31 men showed clinical improvement in plaque size and resolution of penile pain within 4 weeks of treatment without significant adverse reactions.…”

Section: Intralesional Collagenasementioning

confidence: 99%

Nonsurgical treatment options in Peyronie’s Disease: 2016 update

Talib

Ibrahim

Cangüven

2016

Turkish Journal of Urology

View full text Add to dashboard Cite

Peyronie's disease (PD) is an inflammatory condition of penile tunica albuginea which commonly ends with penile curvature and difficulty in vaginal penetration. Unfortunately, the pathophysiology of PD has not been completely understood. In this paper, we will review what is known about the pathophysiology of PD and the nonsurgical medical treatment options that have been trialed as a result. In the last 5 years, commonly used oral medications left their places to intralesional therapies. Clostridium collagenase, which is the only Food and Drug Administration (FDA) approved treatment for PD, is now the most prescribed intralesional therapy in the last years. Clostridium collagenase is advised for patients whose penile curvature is > 30° and < 90°. Because of its side effects, patients should be counseled before intralesional Clostridium collagenase treatment. Until finding best treatment solution for PD, more investigations in regards to the basic science of PD need to be carried out in order to elucidate the exact mechanisms of the fibrosis.

show abstract

“…Gelbard et al 56,57 were the first to study clostridial collagenase in vitro for the treatment of PD in 1982.…”

Section: Collagenasementioning

confidence: 99%